Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

INTRODUCTION: Afatinib is an effective first-line treatment in patients with epidermal growth factor receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in patients progressing on EGFR-tyrosine kinase inhibitors (TKIs). First-line afatinib is also effective in patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Hoffknecht, Petra, Tufman, Amanda, Wehler, Thomas, Pelzer, Theo, Wiewrodt, Rainer, Schütz, Martin, Serke, Monika, Stöhlmacher-Williams, Jan, Märten, Angela, Maria Huber, Rudolf, Dickgreber, Nicolas J.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4276567/
https://ncbi.nlm.nih.gov/pubmed/25247337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados